Skip to content
Home/Companies/Biotech/Inscripta
Inscripta

Inscripta

Biotech·US·Active·8yr hold
Entry
2018
Hold
8yr
Status
Active

Who owns Inscripta?

Inscripta is an American Biotech company, currently owned by Merieux Equity Partners since 2018.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQUS
SectorBiotech
StatusActive
Websitewww.inscripta.com

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
InnoSyn
InnoSyn
Active
PharmaNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Inscripta?

Inscripta is currently owned by Merieux Equity Partners, through Mérieux Innovation 1, since 2018.

When did Merieux Equity Partners acquire Inscripta?

Merieux Equity Partners acquired Inscripta in 2018.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue